Adocia
France - LyonBiotechnology
Focus: Adocia is a France-based biotechnology company specializing in molecular delivery systems (BioChaperone platform) for therapeutic proteins, focused on metabolic diseases. The company is advancing a portfolio of insulin and growth factor formulations through early-to-mid-stage clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Adocia
AI assessmentNot HiringNo open roles listed right now. Follow Adocia to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BioChaperone insulin lispro
Diabetes Mellitus Type 1Clinical Trials (1)
NCT02029924A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
Phase 1Help build intelligence for Adocia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.